课题基金 / 基金详情

Analysis of transforming mechanism of human synovial sarcoma oncogene SYT-SSX

Analysis of transforming mechanism of human synovial sarcoma oncogene SYT-SSX
人滑膜肉瘤癌基因SYT-SSX转化机制分析
批准号:
13557122
负责人:
TANAKA Shinya
金额:
$4.35万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2001
资助国家:
日本
项目状态:
已结题
起止时间:
2001 至 2002

项目摘要

项目成果

TANAKA Shinya的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Human synovial sarcoma occurs primarily around the joint of extremities and more than 90% of cases have chromosomal translocation t(X;18) resulting the formation of chimeric gene SYT-SSX (synovial sarcoma translocation-synovial sarcoma X break point). As both of SYT and SSX did not share any homology region of known functional proteins, the transforming mechanism of SYT-SSX has not yet been elucidated. In this project, we established rat fibroblast cell line 3Y1 expressing SYT, SSX, and SYT-SSX, and found that SYT-SSX induced anchorage-independent growth and tumor formation in nude mice. In this SYT-SSX expressing cell lines, one of the SWI/SNF type of chromatin remodeling factor hBRM has been shown to bind to SYT-SSX and this association was essential for the transformation of 3Y1 cells. Especially, as the disruption of the binding of SYT-SSX and hBRM by specific peptides composed of 50 amino acids corresponding to hBRM155-206, suppressed the growth of SYT-SSX-3Y1 cells, these peptides could be one of the basic technique for the establishment of gene therapy for synovial sarcoma. We also found that in contrast to 3Y1 cells, SYT-SSX induced growth suppression of human adenocarcinoma cell line SW13. In this cell line, SYT-SSX induced p21WAF1/CIP1 expression confirmed by immunoblotting. The luciferase assay using p21 promoter-regulated construction, SYT-SSX was found to activate p21 promoter by transcription factor Sp1-dependent and p53-independent mechanism. Thus, SYT-SSX has differential effect for cell growth such as growth positive and growth negative mechanism, in different cell lines. We are currently considering the augmentation of growth negative function of SYT-SSX may induce the tumor cell suppression as a specific therapy of synovial sarcoma.
期刊论文(220)
专著(0)
科研奖励(0)
会议论文
Ohwatari, R., et al.: "Developmental and functional analyses of CD8^+ NK1.1^+ T cells in the class I restricted TCR transgenic mice"Cell.Immunol.. 213. 24-33 (2001)
Ohwatari, R., et al.:“I 类限制性 TCR 转基因小鼠中 CD8^ NK1.1^ T 细胞的发育和功能分析”Cell.Immunol.. 213. 24-33 (2001)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Nishihara, H., Maeda, M., Tsuda, M., Makino, Y., Sawa, H., Nagashima, K., ^*Tanaka, S.: "DOCK2 mediates T cell receptor-induced activation of Rac2 and IL-2 transcription"Biochem Biophys Res Comm. 296. 716-720 (2002)
Nishihara, H.、Maeda, M.、Tsuda, M.、Makino, Y.、Sawa, H.、Nagashima, K.、^*Tanaka, S.:“DOCK2 介导 T 细胞受体诱导的 Rac2 和 IL 激活
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Ito, M., Abumi, K., Shono, Y., Kotani, Y., Minami, A., Kaneda, K.: "Complications related to hydroxyapatite vertebral spacer in anterior cervical spine surgery"Spine. 27. 428-431 (2002)
Ito, M.、Abumi, K.、Sono, Y.、Kotani, Y.、Minami, A.、Kaneda, K.:“颈椎前路手术中与羟基磷灰石椎体间隔物相关的并发症”脊柱。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Nishihara, H., et al.: "DOCK2 mediates T cell receptor-induced activation of Rac2 and IL-2"Biochem Biophys Res Comm. 296. 716-720 (2002)
Nishihara, H. 等人:“DOCK2 介导 T 细胞受体诱导的 Rac2 和 IL-2 激活”Biochem Biophys Res Comm。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
102
    Development of the nanoporous metal materials as the catalyst in the molecular transformation
    • 批准号:
      23750098
    • 项目类别:
      Grant-in-Aid for Young Scientists (B)
    • 资助金额:
      $2.83万
    • 财政年份:
      2011
    • 负责人:
      TANAKA Shinya
    • 依托单位:
    To clarify the effects of high-fat diet on boon metabolism in ovariectomized mice
    Analysis of synovial sarcoma oncogene SYT-SSX for development of new therapy
    • 批准号:
      19390386
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $10.65万
    • 财政年份:
      2007
    • 负责人:
      TANAKA Shinya
    • 依托单位:
    Analysis of human synovial sarcoma oncoprotein SYT-SSX and its therapeutic application.
    • 批准号:
      16390426
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $7.17万
    • 财政年份:
      2004
    • 负责人:
      TANAKA Shinya
    • 依托单位:
    海外基金